An increasing body of evidence suggests that long noncoding RNAs play critical roles
in human cancer. Breast cancer is a heterogeneous disease and the potential involvement
of long noncoding RNAs in breast cancer remains poorly understood. Herein, researchers
identified a long noncoding RNA, DANCR, which promotes cisplatin chemoresistance in triple-negative breast cancer cells.
Mechanistically, DANCR could bind to Krüppel-like factor 5 (KLF5) and induce acetylation
of KLF5 at lysine 369 (K369), and DANCR knockdown resulted in down-regulation of KLF5 protein levels. Furthermore, researchers
found that the DANCR/KLF5 signaling pathway induced hypersensitivity to cisplatin in chemoresistant patients
by inhibiting p27 transcription. In summary, researcher's study reinforces the potential presence of
a growth regulatory network found in triple-negative breast cancer cells, and a DANCR/KLF5/p27 signaling pathway was documented in the present study that mediates cisplatin chemoresistance
in triple-negative breast cancer.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest. 2011; 121: 2750-2767
- The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res. 2007; 13: 2329-2334
- Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res. 2007; 13: 4429-4434
- Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial.J Clin Oncol. 2018; ([Epub ahead of print] doi:)
- Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.Breast Cancer Res Treat. 2021; 189: 377-386
- LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.Cell Death Dis. 2018; 9: 1167
- Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer.Int J Clin Exp Pathol. 2015; 8: 11480-11484
- Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1.Hepatology. 2016; 63: 499-511
- lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.Cancer Lett. 2017; 405: 46-55
- KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization.J Biol Chem. 2009; 284: 16791-16798
- Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.Oncogene. 2009; 28: 3702-3713
- Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression.Theranostics. 2016; 6: 533-544
- Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation.Cell Discov. 2017; 3: 17010
- An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat Genet. 2008; 40: 499-507
- Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer.Clin Cancer Res. 2006; 12: 2442-2448
- Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens.Endocr Relat Cancer. 2012; 19: 741-750
- Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis.Int J Biol Sci. 2020; 16: 611-619
- LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis.Exp Cell Res. 2020; 396: 112331
- LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.Oncogene. 2018; 37: 4723-4734
- HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation.Biochem Biophys Res Commun. 2018; 500: 777-782
- Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells.J Biol Chem. 2009; 284: 18184-18193
- HDAC2 phosphorylation-dependent Klf5 deacetylation and RARα acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs.Cell Res. 2011; 21: 1487-1508
- The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27 Kip1.Oncotarget. 2015; 6: 17685-17697
- Cisplatin in cancer therapy: molecular mechanisms of action.Eur J Pharmacol. 2014; 740: 364-378
- Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.Cancers (Basel). 2011; 3: 1351-1371
- Excision repair cross complementing-group 1: gene expression and platinum resistance (review) parameters in human breast cancer.Int J Mol Med. 2004; 14: 959-970
- Cisplatin: mode of cytotoxic action and molecular basis of resistance.Oncogene. 2003; 22: 7265-7279
- Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death.Oncotarget. 2015; 6: 30102-30114
- The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.Mol Endocrinol. 2011; 25: 1137-1144
- Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene.Mol Cell Biol. 2001; 21: 562-574
- Identification of Wnt responsive genes using a murine mammary epithelial cell line model system.BMC Dev Biol. 2004; 4: 6
- Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases.Cell Mol Life Sci. 2009; 66: 2691-2706
- Dexamethasone induces docetaxel and cisplatin resistance partially through upregulating Krüppel-like factor 5 in triple-negative breast cancer.Oncotarget. 2017; 8: 11555-11565
- FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells.Mol Cancer Ther. 2008; 7: 3237-3246
- KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression.Cell Prolif. 2013; 46: 425-435
- Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1alpha-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.J Transl Med. 2018; 16: 164
- A positive feedback loop of long noncoding RNA LINC00152 and KLF5 facilitates breast cancer growth.Front Oncol. 2021; 11: 619915
- The long non-coding RNA-DANCR exerts oncogenic functions in non-small cell lung cancer via miR-758-3p.Biomed Pharmacother. 2018; 103: 94-100
- Long non-coding RNA DANCR promotes colorectal cancer proliferation and metastasis via miR-577 sponging.Exp Mol Med. 2018; 50: 1-17
- Long non-coding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.Oncotarget. 2016; 7: 37868-37881
- Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.Neurochem Int. 2018; 118: 233-241
- Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.Breast Cancer Res. 2004; 6: 13-21
- KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation.Cell Death Dis. 2019; 10: 373
Article info
Publication history
Published online: December 09, 2022
Accepted:
November 22,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
Supported in part by Zhejiang Provincial Nature Science Foundation of China grant LQ20H160063 (J.T.); Gansu Provincial National Science Foundation for Distinguished Young Scholars grant 21JR7RA389 (J.T.); and the Science and Technology Program of Gansu Province grant 20JR5RA134 (H.Z.).
A.S. and K.Y. contributed equally to this work.
Disclosures: None declared.
Identification
Copyright
© 2022 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
